Drug Profile
Research programme: anticancer therapeutics - Ablynx/Genencor
Alternative Names: Research programme: anticancer nanobodies - Ablynx/GenencorLatest Information Update: 22 Jun 2018
Price :
$50
*
At a glance
- Originator Ablynx; Genencor International
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 19 Jun 2018 Ablynx has been acquired by Sanofi
- 18 May 2006 Discontinued - Preclinical for Solid tumours in USA (Injection)
- 13 Jun 2005 Genencor International has been acquired by Danisco A/S